Search results for "Gastric mucosa"

showing 10 items of 94 documents

Differential Effects of Verapamil on Various Gastric Lesions in Rats

1988

Verapamil (3, 10, 20 mg/kg-1) increases the necrotizing effects of oral 25% NaCl or 100% ethanol. Damage by 0.6 N HCl was not equally affected since 1 mg/kg-1 of verapamil decreased the ulcer index whereas the higher doses augmented it. Pharmacologically induced gastric lesions were also differently affected by verapamil, ulcers produced by histamine being greatly enhanced and those of reserpine inhibited. Neither indomethacin nor compound 48/80 ulcers were modified. These results suggest that verapamil modifies the susceptibility of the gastric mucosa to damage.

Malemedicine.medical_specialtyGastroenterologyLesionchemistry.chemical_compoundInternal medicinemedicineAnimalsStomach UlcerPharmacologyEthanolDose-Response Relationship Drugbusiness.industryStomachRats Inbred StrainsGeneral MedicineGastric lesionsDifferential effectsRatsEndocrinologymedicine.anatomical_structureVerapamilchemistryGastric MucosaVerapamilFemalemedicine.symptombusinessmedicine.drugPharmacology
researchProduct

Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.

2007

Antisecretory drugs are effective antiulcer agents, but its chronic use generates hypergastrinemia and accelerates the development of atrophic gastritis in Helicobacter pylori-positive patients. We have recently shown that gastrin exerts a proinflammatory effect in rats through CCK-2 receptor activation that contributes to the inflammation induced by H. pylori. The present study was designed to examine whether gastrin hypersecretion in response to treatment with antisecretory drugs induces an inflammatory response that could promote mucosal atrophy. The effects of omeprazole or famotidine on leukocyte/endothelial cell interactions in vivo were analyzed in rat mesenteric venules using intrav…

Malemedicine.medical_specialtyProglumidemedicine.drug_classInflammationCD18Cell CommunicationProinflammatory cytokineRats Sprague-DawleyInternal medicineGastrinsmedicineLeukocytesAnimalsOmeprazoleGastrinPharmacologyInflammationMicroscopy Videobusiness.industryEndothelial CellsProton Pump InhibitorsReceptor antagonistAnti-Ulcer AgentsFlow CytometryImmunohistochemistryReceptor Cholecystokinin BRatsFamotidineChemotaxis LeukocyteEndocrinologyGastric MucosaMolecular Medicinemedicine.symptombusinessmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct

Molecular detection of Helicobacter pylori in oral samples from patients suffering digestive pathologies

2010

Objective: to determine the simultaneous presence of H. pylori in both the oral cavity and gastric mucosal in patients suffering digestive pathologies and to establish the possible association between the presence of H. pylori in the oral cavity and the gingivoperiodontal pathology. Study design: Patients with gastric symptoms (case group) and asymptomatic patients (control group) seen at the Gastroenterology Department of Dr. Julio C. Perrando Hospital (Resistencia, Argentina) were selected. Dental plaque and saliva samples from both groups were obtained. In the case group, gastric biopsy samples were also taken. H. pylori was detected in gastric biopsies by histological stains, and Polyme…

AdultMalemedicine.medical_specialtySalivaPathologyAdolescentDigestive System DiseasesDental PlaqueDiseaseDental plaqueGastroenterologyAsymptomaticlaw.inventionYoung AdultlawInternal medicineMedicineHumansYoung adultRisk factorChildSalivaGeneral DentistryPolymerase chain reactionAgedMouthbiologyHelicobacter pyloribusiness.industryHelicobacter pyloriMiddle Agedbiology.organism_classificationmedicine.disease:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseasesOtorhinolaryngologyMolecular Diagnostic TechniquesGastric MucosaChild PreschoolUNESCO::CIENCIAS MÉDICASSurgeryFemalemedicine.symptombusiness
researchProduct

One-step polymerase chain reaction-based typing of Helicobacter pylori vacA gene: association with gastric histopathology.

2000

Heterogeneity of the Helicobacter pylori vacA gene may be associated with bacterial virulence and presentation. In this study, the possible correlation between vacA genotypes and gastric histopathology was investigated. Using a modified one-step polymerase chain reaction (PCR)-based method, 122 of 131 H. pylori isolates obtained from 63 of 67 patients from Germany were classified into distinct vacA genotypes according to their signal sequence (s1 or s2) and their midregion alleles (m1 or m2). A possible subtype of m1, now alluded to as m3, was identified in one-third of the isolates. Signal sequence s1 was significantly associated with higher H. pylori density but not with gastric inflammat…

Microbiology (medical)AdultDNA BacterialMaleAdolescentGenotypeSpirillaceaeImmunologyPeripheral blood mononuclear cellPolymerase Chain ReactionMicrobiologylaw.inventionHelicobacter InfectionsBacterial ProteinslawGenotypemedicineImmunology and AllergyCagAHumansTypingChildPolymerase chain reactionAntigens BacterialbiologyHelicobacter pyloriGeneral MedicineHelicobacter pyloriMiddle Agedbacterial infections and mycosesbiology.organism_classificationdigestive system diseasesBacterial Typing TechniquesGastric MucosaChild PreschoolGastritisFemaleGastritismedicine.symptomMedical microbiology and immunology
researchProduct

The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas

1993

The differentiation of the predominant cell types of the mucosal epithelium of the mammalian gastrointestinal tract is characterized by increasing amounts of an intermediate-sized filament (IF) protein designated cytokeratin (CK) 20 which is a major cellular protein of mature enterocytes and goblet cells. Here we report the isolation of the human gene encoding CK 20, its complete nucleotide sequence and the amino acid sequence deduced therefrom that identifies this polypeptide (mol. wt. 48553) as a member of the type I-CK subfamily. Remarkable, however, is the comparably great sequence divergence of CK 20 from all other known type I-CKs, with only 58% identical amino acids in the conserved …

Cancer ResearchCell typeMolecular Sequence DataGene ExpressionKeratin-20AdenocarcinomaBiologyImmunoenzyme TechniquesEmbryonic and Fetal DevelopmentCytokeratinIntermediate Filament ProteinsIntestinal mucosaGastric mucosamedicineHumansAmino Acid SequenceRNA MessengerNorthern blotCloning MolecularMolecular BiologyCells CulturedGastrointestinal NeoplasmsGastrointestinal tractBase SequenceSequence Homology Amino AcidCell BiologyMolecular biologyIntestinesmedicine.anatomical_structureGenetic CodeCell cultureImmunologyEnterochromaffin cellDevelopmental BiologyDifferentiation
researchProduct

Hsp60 quantification in human gastric mucosa shows differences between pathologies with various degrees of proliferation and malignancy grade

2021

Background: Stomach diseases are an important sector of gastroenterology, including proliferative benign

0301 basic medicineTechnologyPathologymedicine.medical_specialtyQH301-705.5QC1-999intestinal metaplasia03 medical and health sciences0302 clinical medicinechaperone systemMetaplasiamedicineGastric mucosaGeneral Materials ScienceBiology (General)QD1-999Instrumentationhealth care economics and organizationsFluid Flow and Transfer Processesbusiness.industryChaperone system Gastric carcinogenesis Gastric dysplasia Gastritis Hsp60 Intestinal metaplasiaSettore BIO/16 - Anatomia UmanaTPhysicsProcess Chemistry and TechnologyStomachdigestive oral and skin physiologygastritisGeneral EngineeringIntestinal metaplasiagastric dysplasiaEngineering (General). Civil engineering (General)Hsp60medicine.diseasedigestive system diseasesComputer Science ApplicationsChemistryGastric Dysplasia030104 developmental biologymedicine.anatomical_structureHyperplastic PolypDysplasia030220 oncology & carcinogenesisgastric carcinogenesisTA1-2040medicine.symptomGastritisbusiness
researchProduct

Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma : Updated r…

2019

16 Background: Physiologically, the tight junction protein CLDN18.2 is present only in the gastric mucosa. Upon malignant transformation, CLDN18.2 epitopes are exposed on the cell surface and accessible to targeted therapy. Zolbetuximab (formerly IMAB362) is a chimeric mAb that mediates specific killing of CLDN18.2+ cancer cells through immune effector mechanisms; single-agent activity has been reported in G/GEJ cancer. Methods: Patients (pts) with advanced HER2-negative (HER–) G/GEJ cancer with CLDN18.2 expression of ≥ 2+ staining intensity with the anti-CLDN18 43-14A mAb in ≥ 40% tumor cells were eligible (NCT01630083). Patients were randomized 1:1 to receive first-line EOX ± zolbetuxima…

Cancer ResearchTight junctionbusiness.industryCellMedizinmedicine.diseaseGastroesophageal JunctionEpitopeMalignant transformation03 medical and health sciences0302 clinical medicineFirst line therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchGastric mucosaMedicineAdenocarcinomabusiness030215 immunology
researchProduct

Molecular characterisation and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer.

2009

NUCB2 is an EF-hand Ca2+ binding protein that has been implicated in various physiological processes like calcium homeostasis, hypothalamic regulation of feeding and TNF receptor shedding. In our previous study we identified NUCB2 as a potential tumour antigen eliciting autoantibody responses in 5.4% of gastric cancer patients but not in the healthy individuals.The current study aimed to elucidate the molecular mechanism underlying NUCB2 immunogenicity and to gain an insight into the physiological functions of NUCB2 in the stomach. mRNA expression analysis demonstrated that NUCB2 is ubiquitously expressed in normal tissues, including lymphoid tissues, and downregulated in gastric tumours wh…

AdultMalePathologymedicine.medical_specialtyHistologyNUCB2BiophysicsDown-RegulationNerve Tissue ProteinsBiologyAntigenWestern blotchief cellsParietal Cells GastricStomach NeoplasmsGastric glandsGastric mucosamedicineHumansNucleobindinsEnterochromaffin-like celllcsh:QH301-705.5AgedAutoantibodiesAged 80 and overOriginal Papermedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionStomachgastric cancerCalcium-Binding Proteinsparietal cellsCell BiologySEREXMiddle AgedMolecular biologyGastric chief cellDNA-Binding Proteinsmedicine.anatomical_structurelcsh:Biology (General)Gastric MucosaGastritisCancer cellpepsinogen secretion.Femaletumour-associated antigensProtein Processing Post-TranslationalEuropean journal of histochemistry : EJH
researchProduct

Nitrergic modulation of gastrointestinal function during early endotoxemia.

2006

After bacterial infection, the host reacts by signalling to the central nervous system where a cascade of physiologic, neuroendocrine and behavioural processes is orchestrated, collectively termed the acute phase response. Endotoxemia following Gram-negative bacterial infection induces a wide array of effects, including fever, loss of appetite and changes in gastrointestinal function that attempt to eliminate the challenge and restore homeostasis. Systemic administration of low doses of endotoxin (5-40 microg/kg) to rats is associated with changes in gastrointestinal motor function, inhibition of gastric acid secretion and increase in the gastric mucosal resistance to damage. These changes …

Central Nervous Systemmedicine.medical_specialtyCentral nervous systemMyenteric PlexusNitric OxideNitric oxideGastric Acidchemistry.chemical_compoundInternal medicineNitrergic NeuronsDrug DiscoverymedicineAnimalsHumansPharmacologyGastrointestinal tractbiologyStomachVagus NerveEndotoxemiaRatsNitric oxide synthaseGastrointestinal Tractmedicine.anatomical_structureEndocrinologychemistryGastric MucosaRegional Blood Flowbiology.proteinGastric acidNitric Oxide SynthaseGastrointestinal functionGastrointestinal MotilityHomeostasisCurrent pharmaceutical design
researchProduct

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

2010

Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes. None of the patie…

OncologyMaleSettore MED/06 - Oncologia MedicaPhysiologymedicine.medical_treatmentClinical BiochemistryNucleoside transporterEquilibrative nucleoside transporter 1Cohort StudiesMedicineNeoplasm MetastasisAged 80 and overbiologyMiddle AgedPrognosisImmunohistochemistryFludarabineSurvival RateDisease ProgressionFemalemedicine.drugAdultmedicine.medical_specialtyNucleoside transporterAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalEquilibrative Nucleoside Transporter 1Predictive Value of TestsStomach NeoplasmsPancreatic cancerInternal medicineBiomarkers TumorHumansSurvival rateAgedRetrospective Studiesbusiness.industryCancerCell Biologymedicine.diseaseGemcitabineRadiation therapyDrug Resistance NeoplasmGastric MucosaImmunologybiology.proteinNeoplasm Recurrence LocalbusinessJournal of cellular physiology
researchProduct